No Prescription |
 |
 | ||
|
Daivonex Generic Calcipotriol |
|
| ||
No Prescription » Prescription Drugs 5 » Daivonex Generic Calcipotriol DAIVONEX is an anti-psoriasis medicine. DAIVONEX contains calcipotriol (related to Vitamin D). DAIVONEX does not contain steroids.DAIVONEX is used only on skin affected by psoriasis. Psoriasis is a skin disorder in which skin cells are overactive. The calcipotriol in DAIVONEX treats the overactive skin cells.DAIVONEX is used in the commonest type of psoriasis where "plaques" form in the skin. Plaques are raised rough reddened areas covered with fine dry silvery scales. Plaques are usually a centimetre or two across.DAIVONEX preparations are available as ointment cream and scalp solution.DAIVONEX preparations are available only with a doctor's prescription.This medicine is not expected to affect your ability to drive a car or operate machinery.This medicine is not addictive.Do not use DAIVONEX if you have an allergy to:#any medicine containing calcipotriol #any of the ingredients listed at the end of this leaflet (see Product description). #Some of the symptoms of an allergic reaction include shortness of breath wheezing or difficulty breathing; swelling of the face lips tongue or other parts of the body; rash itching or "hives" on the skin.Do not use DAIVONEX for severe widespread psoriasis or the types of psoriasis known as guttate generalised pustular or erythrodermic exfoliative psoriasis. Your doctor will identify these conditions for you.Do not use DAIVONEX if you#have high blood calcium levels. #are taking calcium vitamin D supplements or vitamin D-like medicines for example calcitriol. Do not use DAIVONEX#after the expiry date printed on the pack OR #if the packaging is torn doesn't look quite right or shows signs of tampering. #If the DAIVONEX packaging is damaged or it is past the expiry date return it to your pharmacist for disposal.Do not breast-feed if you are using DAIVONEX on your breasts.If you are not sure whether you should start using DAIVONEX talk to your doctor.When you must not use DAIVONEX Cream or Scalp SolutionDo not use DAIVONEX cream or scalp solution in children.Safety and effectiveness of these forms of DAIVONEX in children have not been established.DAIVONEX ointment may be used in children (see How to use DAIVONEX).Do not use DAIVONEX cream or scalp solution if you are having other treatments for psoriasis.DAIVONEX ointment may be used with some other treatments for psoriasis. Talk to your doctor to find out if this applies to you. Buy Daivonex Generic Calcipotriol and other Prescription Drugs 5 products online at Medstore. Buy Online at Medstore - Click Here!
About Daivonex Generic Calcipotriol: Product Type: Prescription Drugs 5 Daivonex ( Generic Calcipotriol ) Daivonex (Generic Calcipotriol) Generic Calcipotriol 50mcg/gm 30gm Ointment 50mcg/gm 100gm Cream 50mcg/gm 30gm Ointment 50mcg/gm 100gm Ointment 50mcg/mL 30mL Scalp Solution 50mcg/mL 60mL Scalp Solution Generic Calcipotriol Daivonex
View more Prescription Drugs 5 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
